Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Slides:

Advertisements

Similar presentations

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Advertisements

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.

Immunofluorescence staining of virus-infected human placental explants

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 4. MATE1 transcription in RCC.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 1. PGBD5-expressing cells do not tolerate deficiency of nonhomologous end-joining DNA repair. PGBD5-expressing cells do not tolerate deficiency of.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 4. Features of PH in LLC1 lung tumor mice.

Fig. 2 Adoptive transfer of adult Ox40−/− splenocytes into adult HBVEnvRag−/− mice alters hepatic inflammation, HBsAg clearance, HBsAb seroconversion,

Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile.

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 5 Metarrestin treatment induces nucleolar structure changes.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

PD-L1 is expressed in breast cancer.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

SPARC is required for spontaneous metastasis

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Effects of ZOL treatment on pulmonary metastases.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

SCLC initiated from pulmonary neuroendocrine cells metastasizes without upregulating NFIB. A and B, Mouse models of SCLC. Rb1flox/flox;Trp53flox/flox;p130flox/flox;R26mTmG.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Presentation transcript:

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. (A) Hematoxylin and eosin (H&E) and immunostaining showing the expression of Maraba proteins and cytokeratin-18 in a triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) treated intratumorally with Maraba (n = 2). Scale bars, 200 μm. NV, no virus. (B to D) Quantification of average non-necrotic regions based on H&E staining obtained for the TNBC PDX (B), the luminal B breast cancer PDX (C), or 4T1 tumors (D) (n = 10; Mann-Whitney two-tailed U test, ***P < 0.005). PBS, phosphate-buffered saline. (E and F) Maraba was administered intratumorally to 4T1 tumors before resection, and the spontaneous lung metastases were visualized by histology (E) (n = 6; Mann-Whitney two-tailed U test, **P < 0.01) or India ink perfusion (F) (n = 5 for control and n = 6 for Maraba-treated mice; Mann-Whitney two-tailed U test, *P < 0.05). (G and H) The experiment was repeated in the EMT6 (G; n = 10) and E0771 (H; n = 10) tumor models. Marie-Claude Bourgeois-Daigneault et al., Sci Transl Med 2018;10:eaao1641 Published by AAAS